BioAge Labs (BIOA) Cash from Financing Activities (2023 - 2026)

BioAge Labs has reported Cash from Financing Activities for 4 years, with the latest figure at $123.7 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 8347.67% year-over-year to $123.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $136.7 million (down 35.43% YoY) and the FY2025 annual result came in at $11.5 million, down 96.99% from the prior year.
• Cash from Financing Activities rose to $123.7 million in Q1 2026 per BIOA's latest filing, from $16.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $190.7 million in Q3 2024 and troughed at -$2.4 million in Q2 2024.
• A 4-year average of $51.5 million and a median of $7.5 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities plunged 100.89% in 2025, then surged 8347.67% in 2026.
• Over 4 years, Cash from Financing Activities stood at -$1.0 million in 2023, then soared by 2567.99% to $24.9 million in 2024, then plunged by 35.7% to $16.0 million in 2025, then jumped by 672.59% to $123.7 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $123.7 million, $16.0 million, and -$1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.